Merck Serono Opens New Global Headquarters in Darmstadt

Merck Serono Opens New Global Headquarters in Darmstadt

Modern working environment intended to foster innovation

Darmstadt, Germany, October 10, 2013–Merck Serono, the biopharmaceutical division of Merck, today inaugurated its new global headquarters in Darmstadt, Germany. The opening marks an important milestone in the division's reorganization, which aims to ensure future growth through innovation, backed by highly qualified employees as well as a work culture of entrepreneurial spirit and teamwork. The redesigned buildings in the F-block feature an open office concept intended to encourage project work and collaboration. Of the 1,700 Merck Serono employees in Darmstadt total, around 800 work in two office buildings southeast of Merck's main campus on Frankfurter Strasse.

"Our new Merck Serono headquarters is more than just a redesigned building featuring a modern work environment," said Stefan Oschmann, the Merck Executive Board member responsible for the Pharmaceuticals business. "It stands for a cultural transformation at Merck Serono toward a work style that is just as flexible as it is goal-oriented-one that offers an ideal foundation for the research and development ofinnovative therapies to meet unmet medical needs."

The creation of the new Merck Serono headquarters in Darmstadt is part of the Group-wide "Fit for 2018" transformation program. Within the scope of this initiative, the entire Darmstadt site is being expanded over the next several years into the global headquarters of the Merck Group. "The completion of the new Merck Serono headquarters reflects the continued development of our site," said Kai Beckmann, the Merck Executive Board Member responsible for both the Darmstadt site as well as for Group Human Resources. "We have already filled the key positions for research and development at Merck Serono with highly qualified candidates and anticipate that themodern working environment will help us attract top talent to Merck in the future as well." When Merck Serono moved its headquarters from Geneva to Darmstadt in mid-2012, around 50 Merck Serono employees transferred to Darmstadt.

About Merck Serono

Merck Serono is the biopharmaceutical division of Merck. With headquarters in Darmstadt, Germany,Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.

Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus are as of neurology, oncology, immuno-oncology and immunology.

For more information, please visit
www.merckserono.com
.
Merck is a leading pharmaceutical, chemical and life science company with total revenues of €11.2 billion in 2012, a history that began in 1668, and a future shaped by approx. 38,000 employees in 66 countries.Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

Contact
Gerhard Lerch
Phone +49 6151 72

Suggested Articles

The CD19 antibody, used in tandem with Celgene's Revlimid, represents the first FDA approval in second-line diffuse large B-cell lymphoma.

Sanofi has faced a probe into birth defects tied to seizure med Depakine for years. Now, the investigation is moving forward on manslaughter charges.

Pfizer launched a multichannel awareness campaign centered on a first-ever radio station dedicated solely to metastatic breast cancer.